Remune + ALVAC

Remune + ALVAC is a therapeutic vaccine combination studied for HIV treatment in patients already receiving antiretroviral therapy. The combination aims to enhance immune responses against HIV. **Components:** * **Remune:** An inactivated, gp120-depleted whole HIV-1 virus immunogen emulsified with incomplete Freund's adjuvant. It was designed to boost immune responses, particularly lymphocyte proliferative responses (LPR) to p24, and provide CD4 T-cell help. * **ALVAC (vCP1452):** An HIV canarypox vaccine vector developed to enhance cytotoxic T-lymphocyte responses. **Mechanism:** The combination is based on the rationale that ALVAC could enhance cytotoxic T-lymphocyte responses while Remune would provide CD4 T-cell help, potentially inducing stronger anti-HIV immune responses than either vaccine alone. This aims to augment the containment of viremia provided by antiretroviral agents and extend viral suppression durability. **Clinical Development:** The combination has been studied in clinical trials in HIV-positive patients on antiretroviral therapy. Studies typically randomized patients to different combinations of Remune and ALVAC or placebos. While a study using Remune alone showed no difference in virologic failure compared to placebo, this led to redesigns of protocols for further studies combining Remune with ALVAC. The combination represents an attempt to develop therapeutic vaccines to help control HIV infection long-term.